In an in vitro study, PPARγ agonists inhibited cell proliferation in prostate carcinomas [6,8], but the effects of PPARγ agonists in an in vivo carcinogenesis model were less well described, especially for prostate carcinogenesis. Here, PPARG is linked to prostatitis.